Author

M. Paakkonen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:statistical model· 1

Frequent Co-Authors

O. Kauko· 2 shared A. Hakkinen· 1 shared A. Kaur· 1 shared A. Murgia· 1 shared B. Sahu· 1 shared C. von Schantz-Fant· 1 shared H. Irjala· 1 shared J. L. Griffin· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

O. Kauko

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Lineage-specific oncogenes drive growth of major forms of human cancer using common downstream mechanisms

O. Kauko, M. Turunen, P. Pihlajamaa, A. Hakkinen, R. M. Queiroz, M. Paakkonen, S. Ventela, M. Gaetani, S. Lundstrom, A. Murgia, B. Sahu, J. Routila, H. Irjala, J. L. Griffin, K. S. Lilley, , J. Taipale

The paper identifies common downstream mechanisms driven by lineage-specific oncogenes that regulate cell proliferation in various cancers.

bioRxiv · Sep 27, 2022 · PreprintCancer Biology

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models

O. Denisova, J. Merisaari, R. Huhtaniemi, X. Qiao, A. Kaur, L. Yetukuri, M. Jumppanen, M. Paakkonen, C. von Schantz-Fant, M. Ohlmeyer, K. Wennerberg, O. Kauko, R. Koch, T. Aittokallio, M. Taipale, J. Westermarck

This study identifies a triplet therapy combining AKT, PDK1-4 inhibition, and PP2A reactivation that effectively eradicates brain tumor models by overcoming kinase inhibitor tolerance through combinatorial effects on signaling rewiring, OXPHOS, and apoptosis.

bioRxiv · May 31, 2022 · PreprintCancer Biology